Marco Bolchini, Giulia Ceccardi, Francesca Schiano di Cola, Michele Di Pasquale, Renata Rao, Alessandro Padovani
{"title":"Anti-CGRP monoclonal antibodies, migraine and mood disorders: an observational study.","authors":"Marco Bolchini, Giulia Ceccardi, Francesca Schiano di Cola, Michele Di Pasquale, Renata Rao, Alessandro Padovani","doi":"10.1007/s10072-025-08372-8","DOIUrl":null,"url":null,"abstract":"<p><strong>Introduction: </strong>Migraine is frequently associated with psychiatric comorbidities, especially anxiety and depressive disorders, with related worse clinical outcome and chronicisation. Aim of the study was to assess the effectiveness of anti-CGRP antibodies in alleviating migraine-related symptoms and comorbid anxiety and depressive symptoms.</p><p><strong>Methods: </strong>Retrospective observational study including 206 migraine out-patients in treatment with anti-CGRP antibodies. Beck Depression Inventory (BDI) scale assessing depressive symptoms and Zung Anxiety Scale rating anxiety manifestations, were adopted. Patients were divided into two groups based on the severity of mood disturbances according to BDI score. Effectiveness outcomes (monthly headache days (MHDs), monthly migraine days (MMDs), analgesic consumption, Numerical Rating Scale (NRS), Migraine Disability Assessment (MIDAS) score, Headache Impact Test (HIT-6) score) and self-assessment anxiety and depression scales (BDI, Zung) were analysed after 3 and 6 months of treatment.</p><p><strong>Results: </strong>Effectiveness outcomes showed a significant clinical improvement at T3 (ΔMHD - 9.99 ± 7.82 in Group 1, -10.82 ± 7.62 in Group 2) and T6 (MHD - 10.30 ± 7.41 in Group 1, -10.61 ± 7.87 in Group 2), irrespective of the presence of associated mood symptoms. Treatment resulted in a notable improvement in anxiety and depressive manifestations, with significant reduction in BDI and Zung scales at T3 (ΔBDI - 1.30 ± 3.74 in Group 1, -6.35 ± 11.34 in Group 2) and T6 (ΔBDI - 1.67 ± 4.77 in Group 1, -8.06 ± 10.35 in Group 2).</p><p><strong>Conclusions: </strong>This study corroborates the effectiveness of anti-CGRP antibody treatment in migraine patients, irrespective of the presence of comorbid mood-related symptoms. Furthermore, the persistently favourable outcome in mood symptom severity and intensity throughout the course of treatment substantiates the beneficial impact of this therapeutic approach.</p>","PeriodicalId":19191,"journal":{"name":"Neurological Sciences","volume":" ","pages":""},"PeriodicalIF":2.4000,"publicationDate":"2025-07-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Neurological Sciences","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s10072-025-08372-8","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"CLINICAL NEUROLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Introduction: Migraine is frequently associated with psychiatric comorbidities, especially anxiety and depressive disorders, with related worse clinical outcome and chronicisation. Aim of the study was to assess the effectiveness of anti-CGRP antibodies in alleviating migraine-related symptoms and comorbid anxiety and depressive symptoms.
Methods: Retrospective observational study including 206 migraine out-patients in treatment with anti-CGRP antibodies. Beck Depression Inventory (BDI) scale assessing depressive symptoms and Zung Anxiety Scale rating anxiety manifestations, were adopted. Patients were divided into two groups based on the severity of mood disturbances according to BDI score. Effectiveness outcomes (monthly headache days (MHDs), monthly migraine days (MMDs), analgesic consumption, Numerical Rating Scale (NRS), Migraine Disability Assessment (MIDAS) score, Headache Impact Test (HIT-6) score) and self-assessment anxiety and depression scales (BDI, Zung) were analysed after 3 and 6 months of treatment.
Results: Effectiveness outcomes showed a significant clinical improvement at T3 (ΔMHD - 9.99 ± 7.82 in Group 1, -10.82 ± 7.62 in Group 2) and T6 (MHD - 10.30 ± 7.41 in Group 1, -10.61 ± 7.87 in Group 2), irrespective of the presence of associated mood symptoms. Treatment resulted in a notable improvement in anxiety and depressive manifestations, with significant reduction in BDI and Zung scales at T3 (ΔBDI - 1.30 ± 3.74 in Group 1, -6.35 ± 11.34 in Group 2) and T6 (ΔBDI - 1.67 ± 4.77 in Group 1, -8.06 ± 10.35 in Group 2).
Conclusions: This study corroborates the effectiveness of anti-CGRP antibody treatment in migraine patients, irrespective of the presence of comorbid mood-related symptoms. Furthermore, the persistently favourable outcome in mood symptom severity and intensity throughout the course of treatment substantiates the beneficial impact of this therapeutic approach.
期刊介绍：
Neurological Sciences is intended to provide a medium for the communication of results and ideas in the field of neuroscience. The journal welcomes contributions in both the basic and clinical aspects of the neurosciences. The official language of the journal is English. Reports are published in the form of original articles, short communications, editorials, reviews and letters to the editor. Original articles present the results of experimental or clinical studies in the neurosciences, while short communications are succinct reports permitting the rapid publication of novel results. Original contributions may be submitted for the special sections History of Neurology, Health Care and Neurological Digressions - a forum for cultural topics related to the neurosciences. The journal also publishes correspondence book reviews, meeting reports and announcements.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
